Filing Details

Accession Number:
0001209191-20-055012
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-10-16 12:08:37
Reporting Period:
2020-10-14
Accepted Time:
2020-10-16 12:08:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1683553 Spruce Biosciences Inc. SPRB Pharmaceutical Preparations (2834) 812154263
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1783281 Healthcap Viii, L.p. Avenue D?Ouchy 18
Lausanne V8 CH-1006
No No No Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-10-14 1,783,621 $0.00 1,783,621 No 4 C Direct
Common Stock Acquisiton 2020-10-14 250,000 $15.00 2,033,621 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2020-10-14 11,666,666 $0.00 1,783,621 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
Footnotes
  1. Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020). The shares have no expiration date.
  2. The shares are directly held by HealthCap VIII, L.P. ("HCLP"). HealthCap VIII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over such shares held by HCLP. Jonas Hansson, a Director of the Issuer, has an indirect interest in HCSA and is an employee of HealthCap VIII Advisor AB. Each of the General Partner and Mr. Hansson disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Mr. Hansson is the beneficial owner of such shares.
  3. The shares were purchased in the Issuer's initial public offering.